FDA
-
-
-
-
-
-
-
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
-
-
-
-
-
-
-
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
-
-
-
-
-
-
-
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
-
-
-
-
-
-
-
Here's the list of top biotech stocks to own for 2026
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) PT Raised to $68 at Leerink Partners
-
-
-
-
-
-
-
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
323,944 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

